Lucintel Forecasts the Global Polyamide Resin in the Global Composites Industry Market to reach $9 billion by 2031
According to a market report by Lucintel, the future of the global polyamide resin in the global composites industry market looks promising with opportunities in the transportation, consumer goods, and electrical & electronics applications. The global polyamide resin in the global composites industry market is expected to reach an estimated $9 billion by 2031 with a CAGR of 5% from 2024 to 2031. The major drivers for this market are the increasing use of lightweight, high temperature thermoplastics in under-hood applications and the replacement of metals with polyamide resin based composites in various end uses.
A total of 104 figures / charts and 78 tables are provided in this 157-page report to understand trends, opportunity and forecast in polyamide resin in the global composites industry market to 2031 by end use (transportation, consumer goods, electrical & electronics, and others), resin type (polyamide6, polyamide66, polyamide46, and others), product type (short fiber reinforced thermoplastic (SFT), long fiber reinforced thermoplastic (LFT), and continuous fiber reinforced thermoplastic (CFT), and region (North America, Europe, Asia Pacific and Rest of the World)..
Lucintel forecasts that transportation will remain the largest end use market by value due to high demand for lightweight thermoplastics with high temperature resistant property, which makes polyamide resin suitable for under the hood applications.
SFT will remain the largest market due to its various benefits like ease in processing, low cost production, design flexibility, and the ability to process parts with complex shapes
Download sample by clicking on polyamide resin in the global composites industry market
Asia Pacific and ROW is expected to remain the largest region and witness the highest growth over the forecast period due to growth in construction sector, transportation sector and increasing awareness towards the lightweight thermoplastics with high temperature resistant property.
BASF SE, DSM (Covestro), DuPont, LANXESS AG, Solvay are the major suppliers in the polyamide resin in the global composites industry market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1-972-636-5056
Explore Our Latest Publications
Coating Heads Market
Epoxy Coating Market
Hard Coating Market
Rebar Coating Market
Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email: Send Email
Phone: 972.636.5056
Address: 8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/polyamide-resin-in-the-global-composites-industry.aspx
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
36 minutes ago
- Globe and Mail
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in constant currency Drug Delivery revenue of $10.2 million Gross margin of 69.7%, up 190 basis points over prior year Operating income of $121.1 million, or 18.7% of revenue, up 750 basis points over prior year Adjusted operating income 1 of $115.8 million, or 17.8% of revenue, up 670 basis points over prior year Net income of $22.5 million, or $0.32 per diluted share, compared with $188.6 million, or $2.59 per diluted share in prior year Adjusted net income 1 of $83.7 million, or $1.17 per diluted share, compared with $38.3 million, or $0.55 per diluted share in prior year Adjusted EBITDA 1 of $157.5 million, or 24.3% of revenue, up 570 basis points over prior year Recent Strategic Highlights: Announced Omnipod 5 App for iPhone compatible with Dexcom's G7 Continuous Glucose Monitor (CGM) sensor fully available in the U.S. Integrated Omnipod 5 with Dexcom's G7 CGM sensor in Germany and Abbott's FreeStyle Libre 2 Plus CGM sensor in Australia Collaborated with Marvel to launch comic book hero, Dyasonic, who lives with type 1 diabetes Presented strong clinical data at the American Diabetes Association (ADA) Scientific Session from the Company's SECURE-T2D and RADIANT trials, as well as real-world evidence of improved glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the U.S. Initiated redemption for remaining $380 million principal of convertible notes and refinanced Term Loan B Advanced sustainability across the Company, as detailed in Insulet's 2024 Sustainability Report 2 'We delivered robust second quarter results, reflecting our team's strong performance and the compelling impact and appeal of Omnipod 5 for people living with diabetes,' said Ashley McEvoy, President and CEO. 'Engaging with our partners, physicians, investors, and Podders this quarter has demonstrated our opportunity to revolutionize diabetes management and the value of our unique position at the nexus of consumer health, medtech, and health tech. As we scale the Company, I'm confident in our ability to grow and create value for all our stakeholders in the future.' 2025 Outlook: For the quarter ending September 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency): Conference Call: Insulet will host a conference call at 8:00 a.m. (Eastern Time) on August 7, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company's website at 'Events and Presentations,' and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or Non-GAAP Measures: The Company uses the following non-GAAP financial measures: Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company's results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company's operating results. It is also one of the performance metrics that determines management incentive compensation. Adjusted gross margin, adjusted gross margin as a percentage of revenue, adjusted operating income, adjusted operating income as a percentage of revenue, adjusted net income, and adjusted diluted earnings per share exclude the impact of certain significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, that affect the period-to-period comparability of the Company's performance, as applicable. Adjusted EBITDA, which represents net income plus net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense and other significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, which affect the period-to-period comparability of the Company's performance, as applicable, and adjusted EBITDA as a percentage of revenue. Free cash flow, which is defined as net cash provided by operating activities less capital expenditures. Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures in assessing the Company's performance, and the Company believes they are helpful to investors and other interested parties as measures of comparative performance from period to period. They also are commonly used measures in determining business value, and the Company uses them internally to report results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with GAAP. Furthermore, the Company's definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, Insulet strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Forward-Looking Statement: This press release contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. If management's underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by the forward-looking statements. Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impact of healthcare reform laws; our ability to design, develop, manufacture and commercialize future products; unfavorable results of clinical studies, including issues with third parties conducting any studies, or future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable; our ability to protect our intellectual property and other proprietary rights; potential conflicts with the intellectual property of third parties; our inability to maintain or enter into new license or other agreements with respect to continuous glucose monitors, data management systems or other rights necessary to sell our current product and/or commercialize future products; worldwide macroeconomic and geopolitical uncertainty, as well as risks associated with public health crises and pandemics, including government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; international regulatory, commercial and logistics business risks, including the implementation of tariffs; the potential violation of anti-bribery/anti-corruption laws; the concentration of manufacturing operations and storage of inventory in a limited number of locations; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelligence tools; adverse regulatory or legal actions relating to current or future Omnipod products; potential adverse impacts resulting from a recall, or discovery of serious safety issues, or product liability lawsuits relating to off-label use; breaches or failures of our product or information technology systems, including by cyberattack; our ability to attract, motivate, and retain key personnel; risks associated with potential future acquisitions or investments in new businesses; ability to raise additional funds on acceptable terms or at all; the volatility of the trading price of our common stock; and changes in tax laws or exposure to significant tax liabilities. For a further list and description of these and other important risks and uncertainties that may affect the Company's future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which the Company may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q the Company has filed or will file hereafter. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Three Months Ended June 30, Six Months Ended June 30, (dollars in millions, except per share data) 2025 2024 2025 2024 Revenue $ 649.1 $ 488.5 $ 1,218.1 $ 930.2 Cost of revenue 196.9 157.6 356.8 292.5 Gross profit 452.2 330.9 861.3 637.7 Research and development expenses 73.4 53.9 133.0 104.1 Selling, general and administrative expenses 257.7 222.5 518.4 422.2 Operating income 121.1 54.5 209.9 111.5 Interest expense, net (9.5 ) (1.7 ) (8.5 ) (3.0 ) Loss on extinguishment of debt (84.4 ) — (123.9 ) — Other income (expense), net 1.3 (1.8 ) (0.9 ) (2.5 ) Income before income taxes 28.4 51.1 76.5 106.0 Income tax (expense) benefit (5.9 ) 137.5 (18.6 ) 134.1 Net income $ 22.5 $ 188.6 $ 57.9 $ 240.1 Earnings per share: Basic $ 0.32 $ 2.69 $ 0.82 $ 3.43 Diluted $ 0.32 $ 2.59 $ 0.82 $ 3.32 Weighted-average number of common shares outstanding (in thousands): Basic 70,389 70,062 70,330 70,010 Diluted 70,652 73,802 70,641 73,771 Three Months Ended June 30, Six Months Ended June 30, (in millions) 2025 2024 2025 2024 Net income $ 22.5 $ 188.6 $ 57.9 $ 240.1 Add back interest expense, net of tax attributable to assumed conversion of convertible notes — 2.5 — 4.9 Net income, diluted $ 22.5 $ 191.1 $ 57.9 $ 245.0 Note: May not add or recalculate due to rounding. INSULET CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (dollars in millions) June 30, 2025 December 31, 2024 ASSETS Cash and cash equivalents $ 1,121.6 $ 953.4 Accounts receivable, net 444.5 365.5 Inventories 446.9 430.4 Prepaid expenses and other current assets 266.7 142.0 Total current assets 2,279.7 1,891.3 Property, plant and equipment, net 720.4 723.1 Other intangible assets, net 102.3 98.5 Goodwill 51.7 51.5 Other assets 315.1 323.3 Total assets $ 3,469.2 $ 3,087.7 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable $ 96.1 $ 19.8 Accrued expenses and other current liabilities 453.4 424.9 Current portion of long-term debt 460.7 83.8 Total current liabilities 1,010.1 528.4 Long-term debt, net 939.0 1,296.1 Other liabilities 57.1 51.7 Total liabilities 2,006.3 1,876.1 Stockholders' equity 1,462.9 1,211.6 Total liabilities and stockholders' equity $ 3,469.2 $ 3,087.7 Note: May not add due to rounding. INSULET CORPORATION Three Months Ended June 30, (dollars in millions) 2025 2024 Percent Change Currency Impact Constant Currency U.S. $ 453.2 $ 352.3 28.7 % — % 28.7 % International 185.8 128.2 45.0 % 6.2 % 38.8 % Total Omnipod Products 639.0 480.4 33.0 % 1.6 % 31.4 % Drug Delivery 10.2 8.1 25.7 % — % 25.7 % Total $ 649.1 $ 488.5 32.9 % 1.6 % 31.3 % Six Months Ended June 30, (dollars in millions) 2025 2024 Percent Change Currency Impact Constant Currency U.S. $ 854.9 $ 670.0 27.6 % — % 27.6 % International 338.1 243.4 38.9 % 1.4 % 37.5 % Total Omnipod Products 1,193.0 913.4 30.6 % 0.4 % 30.2 % Drug Delivery 25.1 16.8 49.2 % — % 49.2 % Total $ 1,218.1 $ 930.2 30.9 % 0.4 % 30.6 % Note: Columns and rows may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. ADJUSTED OPERATING INCOME, NET INCOME & DILUTED EPS Three Months Ended June 30, 2025 (in millions, except per share data) Operating Income Percent of Revenue Income before Income Taxes Net Income (4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rates GAAP $ 121.1 18.7 % $ 28.4 $ 22.5 $ 22.5 $ 0.32 20.8 % CEO transition costs (1) (5.3 ) (5.3 ) (5.5 ) (5.5 ) $ (0.08 ) Loss on extinguishment of debt (2) — 84.4 84.1 84.1 $ 1.16 Tax matters (3) — — (17.3 ) (17.3 ) $ (0.24 ) Interest expense, net of tax attributable to assumed conversion of convertible notes — — — 1.2 $ 0.02 Non-GAAP $ 115.8 17.8 % $ 107.5 $ 83.7 $ 85.0 $ 1.17 22.1 % Six Months Ended June 30, 2025 (in millions, except per share data) Operating Income Percent of Revenue Income before Income Taxes Net Income (4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rates GAAP $ 209.9 17.2 % $ 76.5 $ 57.9 $ 57.9 $ 0.82 24.3 % CEO transition costs (1) (5.3 ) (5.3 ) (5.5 ) (5.5 ) $ (0.07 ) Loss on investments (5) 4.7 7.5 5.8 5.8 $ 0.08 Loss on extinguishment of debt (2) — 123.9 123.0 123.0 $ 1.68 Tax matters (3) — — (23.8 ) (23.8 ) $ (0.32 ) Interest expense, net of tax attributable to assumed conversion of convertible notes — — — 2.9 $ 0.04 Non-GAAP $ 209.2 17.2 % $ 202.6 $ 157.4 $ 160.3 $ 2.19 22.3 % (1) Relates to the forfeiture of equity awards by the Company's former Chief Executive Officer, net of severance benefits. (2) Relates to the repurchase of a portion of the Company's convertible debt. (3) Primarily represents consolidating effective tax rate adjustment related to non-GAAP items and excess tax benefits related to employee share-based compensation. (4) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates. (5) Represents a provision for credit loss included in selling, general and administrative expenses related to a debt investment and an impairment included in other expense related to an equity investment. DILUTED SHARES (in thousands) Three Months Ended June 30, 2025 Six Months Ended June 30, 2025 GAAP weighted average number of common shares outstanding, diluted 70,652 70,641 Convertible notes 1,862 2,671 Non-GAAP weighted average number of common shares outstanding, diluted 72,514 73,312 Note: Columns and rows may not add due to rounding or the difference in diluted shares on a GAAP and non-GAAP basis. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. INSULET CORPORATION Three Months Ended June 30, 2024 (dollars in millions) Income before Income Taxes Net Income (3) Net Income, Diluted Diluted Earnings per Share Effective Tax Rate GAAP $ 51.1 $ 188.6 $ 191.1 $ 2.59 (269.3 )% Loss on investments (1) 1.8 1.4 1.4 0.02 Tax matters (2) — (151.7 ) (151.7 ) (2.06 ) Non-GAAP $ 52.8 $ 38.3 $ 40.8 $ 0.55 27.6 % Six Months Ended June 30, 2024 (dollars in millions) Income before Income Taxes Net Income (3) Net Income, Diluted Diluted Earnings per Share Effective Tax Rate GAAP $ 106.0 $ 240.1 $ 245.0 $ 3.32 (126.6 )% Loss on investments (1) 1.8 1.4 1.4 0.02 Tax matters (2) — (158.3 ) (158.3 ) (2.15 ) Non-GAAP $ 107.7 $ 83.2 $ 88.2 $ 1.19 22.8 % (1) Represents non-operating loss resulting from the fair value adjustment of a strategic debt investment. (2) Includes tax benefit of $146.9 million and $153.5 million for the three and six months ended June 30, 2024, respectively, resulting from the release of the majority of the Company's income tax valuation allowance. Both periods also include a $4.8 million tax benefit related to a research and development tax credit recovery project for tax years 2017 through 2021. (3) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates. Note: Columns and rows may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. ADJUSTED EBITDA Three Months Ended June 30, Six Months Ended June 30, (dollars in millions) 2025 Percent of Revenue 2024 Percent of Revenue 2025 Percent of Revenue 2024 Percent of Revenue Net income $ 22.5 3.5 % $ 188.6 38.6 % $ 57.9 4.8 % $ 240.1 25.8 % Interest expense, net 9.5 1.7 8.5 3.0 Income tax expense (benefit) 5.9 (137.5 ) 18.6 (134.1 ) Depreciation and amortization 22.3 19.3 44.0 38.0 Stock-based compensation expense (1) 7.5 17.0 25.7 31.2 CEO transition (2) 5.4 — 5.4 — Loss on extinguishment of debt (3) 84.4 — 123.9 — Loss on investments (4) — 1.8 7.5 1.8 Adjusted EBITDA $ 157.5 24.3 % $ 90.9 18.6 % $ 291.5 23.9 % $ 180.0 19.4 % (1) Amounts for both the three and six months ended June 30, 2025 includes $10.8 million reversal of stock-based compensation expense associated with the departure of the Company's former Chief Executive Officer (CEO). (2) Represents severance expense related to the departure of the Company's former CEO. (3) Relates to the repurchase of a portion of the Company's convertible debt. (4) Represents losses associated with debt and equity investments. FREE CASH FLOW (in millions) Six Months Ended June 30, 2025 Net cash provided by operating activities $ 260.3 Capital expenditures (30.9 ) Free cash flow $ 229.4 Note: Columns may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. INSULET CORPORATION Year Ending December 31, 2025 U.S. Omnipod 22% - 25% —% 22% - 25% International Omnipod 37% - 40% 3% 34% - 37% Total Omnipod 26% - 29% 1% 25% - 28% Drug Delivery (30)% - (25)% —% (30)% - (25)% Total 25% - 28% 1% 24% - 27% Three Months Ended September 30, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 21% - 24% —% 21% - 24% International Omnipod 36% - 39% 3% 33% - 36% Total Omnipod 25% - 28% 1% 24% - 27% Drug Delivery (80)% - (75)% —% (80)% - (75)% Total 23% - 26% 1% 22% - 25%
Globe and Mail
36 minutes ago
- Globe and Mail
3 Top Tech Stocks to Buy in August
Key Points Nvidia should see another blowout quarter when it reports earnings on Aug. 27. Alphabet put concerns about its search business to rest. Taiwan Semiconductor's market share as a GPU fabricator is more than 60%. These 10 stocks could mint the next wave of millionaires › While it's important for investors to keep a balanced portfolio, you can't afford to overlook tech stocks in this market. Tech stocks are the muscle behind U.S. markets these days, accounting for 34% of the makeup of the entire S&P 500. They are also outperformers, as the tech-heavy Nasdaq Composite is outperforming both the S&P 500 and the Dow Jones Industrial Average so far this year. The lesson here? You need to have tech stocks in your portfolio if you want to outperform the market. Tech stocks are immensely popular these days as companies are racing to train large language models (LLMs) to customize their platforms with generative artificial intelligence (AI) offerings in order to roll out new services and customer experiences before their competitors. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The race to build AI products is far from over, and buying stocks that will be best positioned to capitalize on the trend is a smart way to invest right now. If you're looking for the best tech stocks for August, I'm recommending Nvidia (NASDAQ: NVDA), Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), and Taiwan Semiconductor Manufacturing (NYSE: TSM). Nvidia The unquestioned leader in tech stocks right now is chipmaker Nvidia. As the creator of the most advanced graphics processing units (GPUs) that top companies use to power their AI platforms, Nvidia has grown to be the most valuable publicly traded company in the world and was the first to crack the $4 trillion milestone. Nvidia's GPUs can be combined with other chips into clusters that can work faster and more powerfully, which is why they are so prized by companies building AI applications. Jon Peddie Research estimates that Nvidia has a staggering 92% of the GPU market. The company will report earnings for its second quarter of fiscal 2026 on Aug. 27, and analysts are expecting another blowout quarter. Of 66 analysts who cover Nvidia on Yahoo! Finance, 59 of them rank Nvidia as a buy or strong buy. Alphabet Alphabet already reported its quarterly earnings, and Wall Street was impressed. Revenue in Q2 was up 14% to 96.4 billion, while net income was up 19% to $28.19 billion. Alphabet's earnings per share also jumped to $2.31, a 22% gain from a year ago. The report was a welcome return to form for Alphabet, which has struggled so far in 2025 amid concerns that platforms such as ChatGPT would eat into the company's massive Google search business. There are also legal issues, as Alphabet is battling with the Justice Department over allegations that it has an illegal monopoly, and there are concerns that the company could be split up. But Alphabet has been able to put those concerns to rest, at least for now. Revenue from Google Cloud was particularly strong in the second quarter, rising 32% to $13.6 billion, as the company's Google AI platform is incorporated into its Chrome browser and Google search engine. Alphabet also saw strong growth in Google Search (revenue was up 11.7%) and Google Advertising (up 10.4%). Alphabet's stock also trades at a low 20.6 price-to-earnings ratio --incredibly attractive for a tech stock that continues to show strong growth. Taiwan Semiconductor Manufacturing This one goes hand-in-hand with Nvidia, really. If you believe in the growth story powering Nvidia's GPUs, then Taiwan Semiconductor, also known as TSMC, has the same kind of tailwinds. TSMC is a fabricator of GPUs -- it doesn't design them, but it is one of the biggest companies in the world that actually makes them for Nvidia and others. It's a rapidly growing field, as Mordor Intelligence says the GPU market will be $82.7 billion this year and explode to $352.5 billion by 2030. TSMC has an estimated 62% market share of the global foundry market, so it's going to benefit no matter which company has the lead in the GPU race over the next decade. Nvidia's major competitor, Advanced Micro Devices, is also a TSMC customer. TSMC is also growing its footprint in the U.S. rapidly, with plans to invest $165 billion in facilities in Arizona that should shield it from any tariff concerns in the future. TSMC's Q2 earnings included revenue of $30.07 billion, up 44.4% from a year ago. The company is projecting Q3 revenue even higher, to be between $31.8 billion and $33 billion. The bottom line Each of these companies is at the forefront of the explosive growth in AI, which is the dominant trend driving the stock market today. All of them would be excellent buys in August to capitalize on the market-driving power of tech stocks. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
36 minutes ago
- Globe and Mail
D-Wave Reports Second Quarter 2025 Results
D-Wave Quantum Inc. (NYSE: QBTS) ('D-Wave' or the 'Company'), a leader in commercial quantum computing systems, software, and services, today announced financial results for its second quarter ended June 30, 2025. 'Our second quarter results show consistently strong performance across a multitude of technical and business metrics,' said Dr. Alan Baratz, CEO of D-Wave. 'During the quarter, we brought to market our sixth-generation quantum computer, signed a memorandum of understanding related to the acquisition of an on-premises system in South Korea, completed physical assembly of the previously announced system at Davidson Technologies, introduced a collection of developer tools to advance quantum AI and machine learning innovation, and ended the quarter with a record $819 million in cash. We're confident in our ability to continue delivering long-term value for our customers, partners and shareholders.' Recent Business and Technical Highlights Announced revenue of $3.1 million for the second quarter of fiscal 2025. This is an increase of $0.9 million, or 42%, from revenue of $2.2 million for the second quarter of fiscal 2024. Completed a successful $400 million At-the-Market (ATM) equity offering, contributing to D-Wave's consolidated cash balance of approximately $819 million as of June 30, 2025, a record quarter-end balance for the Company. The Company intends to use the proceeds from this financing primarily for strategic acquisitions and general corporate purposes including providing additional working capital and funding capital expenditures. Announced the general availability of D-Wave's Advantage2 quantum computer, its most advanced and performant system. The Advantage2 system is a powerful and energy-efficient annealing quantum computer capable of solving computationally complex problems beyond the reach of classical computers. Featuring D-Wave's most advanced quantum processor to date, the Advantage2 system is commercial-grade, and built to address real-world use cases in areas such as optimization, materials simulation and artificial intelligence. The system features increased connectivity, reduced noise, greater coherence, and increased energy scale, all contributing to faster and higher quality solutions. Announced a new strategic development initiative focused on advanced cryogenic packaging. Designed to advance and scale both gate model and annealing quantum processor development, the initiative builds on D-Wave's technology leadership in superconducting cryogenic packaging and will expand its multichip packaging capabilities, equipment, and processes. By bolstering D-Wave's manufacturing efforts with state-of-the-art technology, the Company aims to accelerate its development efforts in support of its aggressive product roadmap on the path to 100,000 qubits. Released a collection of offerings to help developers explore and advance quantum artificial intelligence (AI) and machine learning (ML) innovation, including an open-source quantum AI toolkit and a demo. The quantum AI toolkit enables developers to seamlessly integrate quantum computers into modern ML architectures. The demo illustrates how developers can leverage this toolkit to explore using D-Wave™ quantum processors to generate simple images, reflecting a pivotal step in the development of quantum AI capabilities. Announced a strategic relationship with Yonsei University and Incheon Metropolitan City to accelerate the exploration, adoption and usage of quantum computing in South Korea. Under the terms of the memorandum of understanding (MOU), the three organizations intend to work together to advance mutual research and talent development for quantum computing, provide access to D-Wave's quantum computing systems and services, and collaborate on development of use cases in biotechnology, materials science and other areas. In addition, the MOU facilitates the organizations' efforts towards the acquisition of a D-Wave Advantage2 system at the Yonsei University International Campus in Songdo, Yeonsu-gu, Incheon. Signed a number of new and renewing customer engagements for both commercial and research applications, including – a European multinational electric utility company; GE Vernova – a global energy company; National Quantum Computing Centre (NQCC) – the UK's national lab for quantum computing; Nikon Corporation – a multinational corporation specializing in optics and precision technologies; NTT Data Corp. – a multinational IT services and consulting company; NTT DOCOMO – Japan's leading mobile operator; Sharp Corporation – a multinational electronics company; and the University of Oxford. Second Quarter Fiscal 2025 Financial Highlights Revenue: Revenue for the second quarter of fiscal 2025 was $3.1 million, an increase of $0.9 million, or 42%, from the fiscal 2024 second quarter revenue of $2.2 million. Bookings 1: Bookings for the second quarter of fiscal 2025 were $1.3 million, an increase of $0.6 million, or 92%, from the fiscal 2024 second quarter Bookings of $0.7 million. Customers: For the most recent four quarters, D-Wave had in excess of 100 revenue generating customers. GAAP Gross Profit: GAAP gross profit for the second quarter of fiscal 2025 was $2.0 million, an increase of $0.6 million, or 42%, from the fiscal 2024 second quarter GAAP gross profit of $1.4 million, with the increase due primarily to the growth in revenue. GAAP Gross Margin: GAAP gross margin for the second quarter of fiscal 2025 was 63.8%, an increase of 0.2% from the fiscal 2024 second quarter GAAP gross margin of 63.6%. Non-GAAP Gross Profit 2: Non-GAAP Gross Profit for the second quarter of fiscal 2025 was $2.2 million, an increase of $0.6 million, or 39%, from the fiscal 2024 second quarter Non-GAAP Gross Profit of $1.6 million. The difference between GAAP and Non-GAAP Gross Profit is limited to non-cash stock-based compensation and depreciation and amortization expenses that are excluded from the Non-GAAP Gross Profit. Non-GAAP Gross Margin 2: Non-GAAP Gross Margin for the second quarter of fiscal 2025 was 71.8%, a decrease of 1.3% from the fiscal 2024 second quarter Non-GAAP Gross Margin of 73.1%. The difference between GAAP and Non-GAAP Gross Margin is limited to non-cash stock-based compensation and depreciation and amortization expenses that are excluded from the Non-GAAP Gross Margin. GAAP Operating Expenses: GAAP operating expenses for the second quarter of fiscal 2025 were $28.5 million, an increase of $8.3 million, or 41%, from the fiscal 2024 second quarter GAAP Operating Expenses of $20.2 million with the increase driven primarily by increases of $3.5 million in personnel costs, $2.4 million in non-cash stock-based compensation, $1.6 million in fabrication and related activities and $1.5 million in third party professional fees, partly offset by a recovery on a previously written-off debt of $1.1 million. The increased operating expenses stem from incremental investments to support the Company's continued growth and expansion. Non-GAAP Adjusted Operating Expenses 2: Non-GAAP Adjusted Operating Expenses for the second quarter of fiscal 2025 were $22.2 million, an increase of $6.7 million, or 43% from the fiscal 2024 second quarter Non-GAAP Adjusted Operating Expenses of $15.5 million, with the difference between GAAP and Non-GAAP Adjusted Operating Expenses being primarily non-cash stock-based compensation expense, non-cash depreciation and amortization, and non-recurring one-time expenses. Net Loss: Net loss for the second quarter of fiscal 2025 was $167.3 million, or $0.55 per share, an increase of $149.5 million, or $0.45 per share, from the fiscal 2024 second quarter net loss of $17.8 million, or $0.10 per share. The increase was primarily due to $142.0 million in non-cash, non-operating charges related to the remeasurement of the Company's warrant liability, as well as realized losses stemming from warrant exercises, that materially increased as a result of the significant price appreciation of the Company's warrants. Adjusted Net Loss 2: Adjusted Net Loss for the second quarter of fiscal 2025 was $25.3 million, or $0.08 per share, an increase of $5.3 million, and a decrease of $0.04 per share, from the fiscal 2024 second quarter Adjusted Net Loss of $20.0 million, or $0.12 per share, with the difference between Net Loss and Adjusted Net Loss being non-cash, non-operating warrant remeasurement related charges. Adjusted EBITDA Loss 2: Adjusted EBITDA Loss for the second quarter of fiscal 2025 was $20.0 million, an increase of $6.1 million, or 44%, from the fiscal 2024 second quarter Adjusted EBITDA Loss of $13.9 million with the increase due primarily to higher operating expenses, partly offset by higher gross profit. Financial Results for the First Half of Fiscal Year 2025 Revenue: Revenue for the six months ended June 30, 2025 was $18.1 million, an increase of $13.5 million, or 289%, from revenue of $4.6 million for the six months ended June 30, 2024. Bookings 1: Bookings for the six months ended June 30, 2025 were $2.9 million, a decrease of $0.4 million, or 13%, from Bookings of $3.3 million for the six months ended June 30, 2024. GAAP Gross Profit: GAAP gross profit for the six months ended June 30, 2025 was $15.9 million, an increase of $12.9 million, or 420%, from $3.0 million in GAAP gross profit for the six months ended June 30, 2024, with the increase due primarily to a higher margin annealing quantum computer system sale during the six months ended June 30, 2025. GAAP Gross Margin: GAAP gross margin for the six months ended June 30, 2025 was 87.6%, an increase of 22.0% from the 65.6% GAAP gross margin for the six months ended June 30, 2024, with the increase due primarily to a higher margin annealing quantum computer system sale during the six months ended June 30, 2025. Non-GAAP Gross Profit 2: Non-GAAP Gross Profit for the six months ended June 30, 2025 was $16.3 million, an increase of $12.8 million, or 367%, from the Non-GAAP Gross Profit of $3.5 million for the six months ended June 30, 2024. The difference between GAAP and Non-GAAP Gross Profit is limited to non-cash stock-based compensation and depreciation and amortization expenses that are excluded from the Non-GAAP Gross Profit. Non-GAAP Gross Margin 2: Non-GAAP Gross Margin for the six months ended June 30, 2025 was 89.9%, an increase of 14.9% from the 75.0% Non-GAAP Gross Margin for the six months ended June 30, 2024. The difference between GAAP and Non-GAAP Gross Margin is limited to non-cash stock-based compensation and depreciation and amortization expenses that are excluded from the Non-GAAP Gross Margin. GAAP Operating Expenses: GAAP operating expenses for the six months ended June 30, 2025 were $53.6 million, an increase of $14.2 million, or 36%, from GAAP operating expenses of $39.4 million for the six months ended June 30, 2024, with the year-over-year increase primarily driven by increases of $6.6 million in salaries and related personnel costs, 80% of which relates to increases in Sales & Marketing and Research & Development staff; $2.9 million in non-cash stock-based compensation; $2.0 million in fabrication and related activities; $1.8 million in third party professional services and $1.3 million in marketing expenses. The increased operating expenses stem from incremental investments to support the Company's continued growth and expansion. Non-GAAP Adjusted Operating Expenses 2: Non-GAAP Adjusted Operating Expenses for the six months ended June 30, 2025 were $42.4 million, an increase of $12.1 million, or 40%, from Non-GAAP Adjusted Operating Expenses of $30.3 million for the six months ended June 30, 2024, with the difference between GAAP and Non-GAAP Operating Expenses being primarily non-cash stock-based compensation expense, non-recurring one-time expenses, and depreciation and amortization. Net Loss: Net loss for the six months ended June 30, 2025 was $172.8 million, or $0.59 per share, an increase of $137.7 million, or $0.38 per share, compared with a net loss of $35.1 million, or $0.21 per share for the six months ended June 30, 2024. The increase was primary due to $138.1 million in non-cash, non-operating charges related to the remeasurement of the Company's warrant liability, as well as realized losses stemming from warrant exercises. Adjusted Net Loss 2: Adjusted Net Loss for the six months ended June 30, 2025 was $34.6 million, or $0.12 per share, essentially flat compared with the Adjusted Net Loss of $34.6 million, or $0.21 per share for the six months ended June 30, 2024, with the difference between Net Loss and Adjusted Net Loss being non-cash, non-operating warrant related charges. Adjusted EBITDA Loss 2: The Adjusted EBITDA Loss for the six months ended June 30, 2025 was $26.1 million, a decrease of $0.7 million, or 3%, from the six months ended June 30, 2024 Adjusted EBITDA Loss of $26.8 million, with the improvement due primarily to higher gross profit, partly offset by increased operating expenses. 1 'Bookings' is an operating metric that is defined as customer orders received that are expected to generate net revenues in the future. We present the operational metric of Bookings because it reflects customers' demand for our products and services and to assist readers in analyzing our potential performance in future periods. 2"Non-GAAP Gross Profit", "Non-GAAP Gross Margin", "Non-GAAP Adjusted Operating Expenses", "Adjusted Net Loss", "Adjusted Net Loss per Share" and "Adjusted EBITDA Loss", are non-GAAP financial measures or metrics. Please see the discussion in the section 'Non-GAAP Financial Measures' and the reconciliations included at the end of this press release. Balance Sheet and Liquidity As of June 30, 2025, D-Wave's consolidated cash balance totaled a record $819.3 million, representing an over 1900% increase from the fiscal 2024 second quarter consolidated cash balance of $40.9 million, and a 169% increase from the immediately prior fiscal 2025 first quarter consolidated cash balance of $304.3 million. During the second quarter of fiscal 2025, the Company raised $400 million in gross proceeds from its fourth ATM equity offering program, $99.3 million in cash proceeds from the exercise of warrants, and $37.8 million in net proceeds from its Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC that fulfilled the $150 million commitment that was originally secured in June of 2022. D-Wave ended the second quarter of fiscal 2025 with a record $694.3 million in stockholders' equity. Earnings Conference Call D-Wave will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. (Eastern Time), to discuss the Company's financial results and business outlook. The live dial-in number is 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Participants can use those dial-in numbers or can click this link for instant telephone access to the event. The link will be made active 15 minutes prior to the call's scheduled start time. An on-demand webcast will be available on the D-Wave Investor Relations website after the call. Participating in the call will be Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich. About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world's largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Non-GAAP Financial Measures To supplement the financial information presented in accordance with GAAP, we use non-GAAP measures of certain components of financial performance. Each of Non-GAAP Gross Profit, Non-GAAP Gross Margin, Adjusted EBITDA Loss, Adjusted Net Loss, Adjusted Net Loss per Share and Non-GAAP Adjusted Operating Expenses is a financial measure that is not required by or presented in accordance with GAAP. Management believes that each measure provides investors an additional meaningful method to evaluate certain aspects of such results period over period. The Company defines each of its non-GAAP financial measures as follows: Non-GAAP Gross Profit is defined as GAAP gross profit less non-cash stock-based compensation expense and depreciation and amortization expense. We use Non-GAAP Gross Profit to measure, understand and evaluate our core operating performance and trends and to develop short-term and long-term operating plans. Non-GAAP Gross Margin is defined as GAAP gross margin less non-cash stock-based compensation expense. We use Non-GAAP Gross Margin to measure, understand and evaluate our core business performance. Adjusted EBITDA Loss is defined as net loss before interest expense, income tax expense (benefit), depreciation and amortization expense, stock-based compensation, remeasurements of liability-classified warrants, and other non-recurring non-operating income and expenses. We use Adjusted EBITDA Loss to measure the operating performance of our business, excluding specifically identified items that we do not believe directly reflect our core operations and may not be indicative of our recurring operations. Adjusted Net Loss and Adjusted Net Loss per Share are defined as net loss and net loss per share excluding the impact of the non-cash, non-operating charges associated with the remeasurement of the Company's warrant liability. Non-GAAP Adjusted Operating Expenses is defined as operating expenses before depreciation and amortization expense, non-recurring one-time expenses and non-cash stock-based compensation expense. We use Non-GAAP Adjusted Operating expenses to measure our operating expenses, excluding items we do not believe directly reflect our core operations. The presentation of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the financial results prepared in accordance with GAAP, and our presentation of non-GAAP measures may be different from non-GAAP measures used by other companies. For a reconciliation of each of Non-GAAP Gross Profit, Non-GAAP Gross Margin, Adjusted EBITDA Loss, Adjusted Net Loss, Adjusted Net Loss per Share and Non-GAAP Adjusted Operating Expenses to its most directly comparable GAAP measure, please refer to the reconciliations below. Forward Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law. June 30, December 31, (In thousands, except share and per share data) 2025 2024 Assets Current assets: Cash and cash equivalents $ 819,312 $ 177,980 Trade accounts receivable, net of allowance for doubtful accounts of $1 and $176 1,442 1,420 Inventories 2,448 1,686 Prepaid expenses and other current assets 5,338 3,954 Total current assets 828,540 185,040 Property and equipment, net 4,504 4,133 Operating lease right-of-use assets 6,915 7,261 Intangible assets, net 586 490 Other non-current assets, net 3,057 2,929 Total assets $ 843,602 $ 199,853 Liabilities and stockholders' equity Current liabilities: Trade accounts payable $ 1,190 $ 815 Accrued expenses and other current liabilities 11,582 8,784 Current portion of operating lease liabilities 1,596 1,512 Loans payable, net, current — 348 Deferred revenue, current 4,906 18,686 Total current liabilities 19,274 30,145 Warrant liabilities 91,037 69,875 Operating lease liabilities, net of current portion 6,322 6,389 Loans payable, net, non-current 32,061 30,128 Deferred revenue, non-current 654 670 Total liabilities $ 149,348 $ 137,207 Commitments and contingencies Stockholders' equity: Common stock, par value $0.0001 per share; 675,000,000 shares authorized at both June 30, 2025 and December 31, 2024; 339,837,650 shares and 266,595,867 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. 33 27 Additional paid-in capital 1,503,136 700,069 Accumulated deficit (799,690 ) (626,940 ) Accumulated other comprehensive loss (9,225 ) (10,510 ) Total stockholders' equity 694,254 62,646 Total liabilities and stockholders' equity $ 843,602 $ 199,853 Three Months Ended June 30, Six Months Ended June 30, (In thousands, except share and per share data) 2025 2024 2025 2024 Revenue $ 3,095 $ 2,183 $ 18,096 $ 4,648 Cost of revenue 1,119 795 2,243 1,601 Total gross profit 1,976 1,388 15,853 3,047 Operating expenses: Research and development 12,694 8,355 22,982 16,880 General and administrative 9,151 7,471 17,108 15,037 Sales and marketing 6,633 4,401 13,556 7,485 Total operating expenses 28,478 20,227 53,646 39,402 Loss from operations (26,502 ) (18,839 ) (37,793 ) (36,355 ) Other income (expense), net: Interest expense (206 ) (1,160 ) (432 ) (2,300 ) Change in fair value of Term Loan — (275 ) — 924 Gain (loss) on investment in marketable securities — (157 ) — 1,503 Change in fair value of warrant liabilities (142,048 ) 2,195 (138,105 ) (457 ) Other income (expense), net 1,427 458 3,580 1,595 Total other income (expense), net (140,827 ) 1,061 (134,957 ) 1,265 Net loss $ (167,329 ) $ (17,778 ) $ (172,750 ) $ (35,090 ) Net loss per share, basic and diluted $ (0.55 ) $ (0.10 ) $ (0.59 ) $ (0.21 ) Weighted-average shares used in computing net loss per share, basic and diluted 302,288,793 172,139,085 294,398,419 166,723,787 Comprehensive loss: Net loss $ (167,329 ) $ (17,778 ) $ (172,750 ) $ (35,090 ) Foreign currency translation adjustment 787 22 1,285 69 Net comprehensive loss $ (166,542 ) $ (17,756 ) $ (171,465 ) $ (35,021 ) D-Wave Quantum Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30, (in thousands) 2025 2024 Cash flows from operating activities: Net loss $ (172,750 ) $ (35,090 ) Adjustments to reconcile net loss to cash used in operating activities: Depreciation and amortization 714 510 Stock-based compensation 10,664 7,730 Amortization of operating right-of-use assets 346 398 Non-cash interest expense 387 2,211 Change in fair value of Warrant liabilities 138,105 457 Change in fair value of Term Loan — (924 ) Gain on marketable securities — (1,503 ) Unrealized foreign exchange loss (gain) 1,998 (1,274 ) Other noncash items 267 — Change in operating assets and liabilities: Trade accounts receivable (57 ) 9 Inventories (762 ) (147 ) Prepaid expenses and other current assets (1,368 ) (339 ) Trade accounts payable 416 (502 ) Accrued expenses and other current liabilities 2,695 1,741 Deferred revenue (13,796 ) (125 ) Operating lease liability (344 ) 364 Other non-current assets, net (1,080 ) (103 ) Net cash used in operating activities (34,565 ) (26,587 ) Cash flows from investing activities: Purchase of property and equipment (1,187 ) (850 ) Purchase of convertible note — (1,000 ) Proceeds from recovery of previously written-off convertible receivable 959 — Sales of marketable equity securities — 254 Expenditures for internal-use software (129 ) (213 ) Net cash used in investing activities (357 ) (1,809 ) Cash flows from financing activities: Proceeds from the issuance of common stock pursuant to the Lincoln Park Purchase Agreement 37,787 20,288 Proceeds from the issuance of common stock in at-the-market offerings 536,741 9,100 Proceeds from issuance of common stock upon exercise of warrants 99,319 — Proceeds from the issuance of common stock upon exercise of stock options 6,860 43 Proceeds from common stock issued under the Employee Stock Purchase Plan 291 171 Payment of tax withheld pursuant to stock-based compensation settlements (5,664 ) (1,351 ) Repayments on TPC loan (365 ) (370 ) Net cash provided by financing activities 674,969 27,881 Effect of exchange rate changes on cash and cash equivalents 1,285 69 Net increase (decrease) in cash and cash equivalents 641,332 (446 ) Cash and cash equivalents at beginning of period 177,980 41,307 Cash and cash equivalents at end of period $ 819,312 $ 40,861 Three Months Ended June 30, Six Months Ended June 30, (in thousands of U.S. dollars) 2025 2024 2025 2024 Gross Profit $ 1,976 $ 1,388 $ 15,853 $ 3,047 Gross Margin 63.8 % 63.6 % 87.6 % 65.6 % Excluding: Depreciation and Amortization (1) 14 54 42 109 Stock-based compensation (2) 231 154 373 329 Non-GAAP Gross Profit $ 2,221 $ 1,596 $ 16,268 $ 3,485 Non-GAAP Gross Margin 71.8 % 73.1 % 89.9 % 75.0 % (1) Depreciation and Amortization reflects the Depreciation and Amortization recorded in Cost of Revenue only, which differs from the total Depreciation and Amortization set forth in the Condensed Consolidated Statement of Cash Flows that also includes Depreciation and Amortization recorded in Operating Expenses. (2) Stock-based compensation reflects the stock-based compensation recorded in Cost of Revenue only, which differs from the total stock-based compensation set forth in the Condensed Consolidated Statement of Cash flows that also includes stock-based compensation recorded in Operating Expenses. Three Months Ended June 30, Six Months Ended June 30, (in thousands of U.S. dollars) 2025 2024 2025 2024 Operating expenses $ 28,478 $ 20,227 $ 53,646 $ 39,402 Excluding: Depreciation and Amortization (1) (324 ) (227 ) (672 ) (401 ) Stock-based compensation (2) (6,440 ) (4,067 ) (10,291 ) (7,401 ) Other non-operating or non-recurring expenses (3) 506 (443 ) (304 ) (1,325 ) Non-GAAP Adjusted Operating Expenses $ 22,220 $ 15,490 $ 42,379 $ 30,275 (1) Depreciation and Amortization reflects the Depreciation and Amortization recorded in the Operating Expenses only, which differs from the total Depreciation and Amortization set forth in the Condensed Consolidated Statement of Cash Flows that also includes Depreciation and Amortization recorded in Cost of Revenue. (2) Stock-based compensation reflects the stock-based compensation recorded in Operating Expenses only, which differs from the total stock-based compensation set forth in the Condensed Consolidated Statement of Cash flows that also includes stock-based compensation recorded in Cost of Revenue. (3) Includes legal, consulting, and accounting fees arising from capital markets activities that are unrelated to the Company's core business operations, as well as non-recurring professional fees and credit loss expenses and recoveries. Three Months Ended June 30, Six Months Ended June 30, (in thousands of U.S. dollars) 2025 2024 2025 2024 Net loss $ (167,329 ) $ (17,778 ) $ (172,750 ) $ (35,090 ) Net loss per share (basic and diluted) $ (0.55 ) $ (0.10 ) $ (0.59 ) $ (0.21 ) Excluding: Change in fair value of warrant liabilities 142,048 (2,195 ) 138,105 457 Adjusted net loss $ (25,281 ) $ (19,973 ) $ (34,645 ) $ (34,633 ) Adjusted net loss per share (basic and diluted) $ (0.08 ) $ (0.12 ) $ (0.12 ) $ (0.21 ) D-Wave Quantum Inc. Reconciliation of Net Loss to Adjusted EBITDA Loss (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands of U.S. dollars) 2025 2024 2025 2024 Net loss $ (167,329 ) $ (17,778 ) $ (172,750 ) $ (35,090 ) Excluding: Depreciation and Amortization 338 281 714 510 Stock-based compensation 6,671 4,221 10,664 7,730 Interest expense (1) 206 1,160 432 2,300 Change in fair value of warrant liabilities 142,048 (2,195 ) 138,105 457 Change in fair value of Term Loan — 275 — (924 ) Gain (loss) on investment in marketable securities — 157 — (1,503 ) Other (income) expense, net (2) (1,427 ) (458 ) (3,580 ) (1,595 ) Other non-operating or non-recurring items (3) (506 ) 443 304 1,325 Adjusted EBITDA Loss $ (19,999 ) $ (13,894 ) $ (26,111 ) $ (26,790 ) (1) Interest expense primarily reflects the paid-in-kind interest associated with the term loan agreement with PSPIB Unitas Investments II Inc. entered into on April 13, 2023 and fully repaid on October 22, 2024, and interest and adjustments to accrued interest on the SIF Loan. (2) Other income (expense), net consists primarily of foreign exchange gains and losses and interest income earned from cash and cash equivalents. (3) Includes legal, consulting, and accounting fees arising from capital markets activities that are unrelated to the Company's core business operations, as well as non-recurring professional fees and credit loss expenses and recoveries.
